Search PubMed⌕ Search

Biomedical subjects

M Harms

Publications and source records attributed to M Harms.

At least 91 records · Page 5Linked to original sources
PubMed1983

[Photosensitivity associated with carprofen (Imadyl), a new non-steroidal anti-inflammatory drug].

Carprofen is a new non-steroidal anti-inflammatory drug and a phenylpropionic acid derivative. It seldom causes pruritus, erythema or urticaria. Since 1 year, we have observed 8 photosensitive eruptions associated with Carprofen, a surprising side effect for this group of derivatives. The skin eruption started from 4 days to 3 weeks after the initiation of the treatment and was always limited to the exposed areas of the skin. The eruption was erythematopapular, but also vesioular or bullous. 2 cases required systemic corticosteroids. Photo patch tests were positive, suggesting a photoallergic process. Phototherapy should be avoided in patients treated with carprofen.

Adult↗
PubMed1982

[Genetic aspects of blue rubber-bleb nevus syndrome and multiple generalized glomangiomatosis].

Morphology, clinical findings and histological examination allow to recognize the solitary glomus tumor from the multiple glomus tumors and the blue rubber-bleb nevus-syndrome; however, the latter are more difficult to identify separately. They are transmitted as autosomal dominant conditions with good penetrance. With the hypothesis of a dual mutation system and that of the putative induction of paramutations the authors try to account for the variable expression of these conditions. It may be suggested that the existence of a common histological pattern, the multiple systematic, the multiple generalized tumors and the blue rubber-bleb nevus syndrome being perhaps the different expression of the same basic pathologic process.

Diagnosis, Differential↗
PubMed1982

[Thalidomide in the treatment of chronic lupus erythematosus].

The effect of thalidomide was investigated in 12 patients with chronic lupus erythematosus resistant to classical treatment (antimalarial drugs, topical steroids). 10 patients were improved and 2 were not sensitive to the treatment. The doses were 100 mg/day for a minimum period of 2 months. With the exception of 1 case, the treatment was well tolerated. The indications of thalidomide in dermatology and the mechanism of action of the drug are briefly discussed.

Adult↗